Table 6.

Basophil count by different predictors (UK Biobank). Data are presented as median (IQR).

	Control	Endometriosis	P
n	6331	1537
Total	0.020 (0.050)	0.030 (0.060)
Age group (years)a			0.97
≤42.5	0.020 (0.050)	0.020 (0.050)
42.5–45	0.020 (0.050)	0.030 (0.058)
45–47.5	0.020 (0.060)	0.030 (0.050)
47.5–50	0.020 (0.050)	0.020 (0.060)
WHRa			<0.001*
≤0.75	0.020 (0.050)	0.020 (0.040)
0.75–0.80	0.020 (0.050)	0.030 (0.050)
0.80–0.85	0.020 (0.050)	0.030 (0.060)
>0.85	0.030 (0.060)	0.030 (0.060)
BMI (kg/m²)a			0.003*
≤22.5	0.020 (0.050)	0.020 (0.040)
22.5–25	0.020 (0.050)	0.020 (0.040)
25–30	0.020 (0.050)	0.020 (0.050)
>30	0.030 (0.060)	0.030 (0.075)
Smoking habitb			<0.001*
Never smokers	0.020 (0.050)	0.030 (0.060)
Current smokers	0.030 (0.090)	0.040 (0.070)
Past smokers	0.030 (0.050)	0.020 (0.050)
Exogenous hormoneb			0.22
HRT	0.020 (0.060)	0.050 (0.050)
Oral contraceptive pill	0.030 (0.060)	0.030 (0.050)
None of the two above	0.020 (0.050)	0.030 (0.060)
Hay fever seasonb			<0.001*
Yes	0.020 (0.060)	0.030 (0.060)
No	0.020 (0.030)	0.030 (0.040)
Asthmab			0.25
Yes	0.020 (0.060)	0.030 (0.070)
No	0.020 (0.050)	0.020 (0.050)
Eczemab			0.23
Yes	0.020 (0.040)	0.040 (0.073)
No	0.020 (0.050)	0.030 (0.060)

*P values <0.05 were considered as evidence of a significant difference between comparison groups.

^aP values for trend were derived from ordinal logistic regression models; ^bP values were derived from chi-square tests.

HRT, hormone replacement therapy; WHR, waist-to-hip ratio.